<?xml version="1.0" encoding="UTF-8"?>
<p>Putamina were chosen for bilateral stereotactic delivery of NPCs because this area has been described as the most affected site in the basal ganglia of PD patients. It shows the greatest dopaminergic cell loss
 <sup>
  <xref rid="bibr2-0963689718820271" ref-type="bibr">2</xref>
 </sup> and is linked to levodopa-induced dyskinesias
 <sup>
  <xref rid="bibr9-0963689718820271" ref-type="bibr">9</xref>,
  <xref rid="bibr10-0963689718820271" ref-type="bibr">10</xref>
 </sup>. Encouragingly, unilateral
 <sup>
  <xref rid="bibr58-0963689718820271" ref-type="bibr">58</xref>
 </sup> or bilateral intraputaminal fetal dopaminergic cell grafting
 <sup>
  <xref rid="bibr20-0963689718820271" ref-type="bibr">20</xref>,
  <xref rid="bibr59-0963689718820271" ref-type="bibr">59</xref>,
  <xref rid="bibr60-0963689718820271" ref-type="bibr">60</xref>
 </sup> or unilateral intraputaminal glial cell line-derived neurotrophic factor delivery
 <sup>
  <xref rid="bibr61-0963689718820271" ref-type="bibr">61</xref>,
  <xref rid="bibr62-0963689718820271" ref-type="bibr">62</xref>
 </sup> have led to clinical improvement in patients with PD.
</p>
